110 related articles for article (PubMed ID: 16033950)
21. In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver.
Katoh M; Sawada T; Soeno Y; Nakajima M; Tateno C; Yoshizato K; Yokoi T
J Pharm Sci; 2007 Feb; 96(2):428-37. PubMed ID: 17051594
[TBL] [Abstract][Full Text] [Related]
22. Epitope spreading of the anti-CYP2D6 antibody response in patients with autoimmune hepatitis and in the CYP2D6 mouse model.
Hintermann E; Holdener M; Bayer M; Loges S; Pfeilschifter JM; Granier C; Manns MP; Christen U
J Autoimmun; 2011 Nov; 37(3):242-53. PubMed ID: 21795021
[TBL] [Abstract][Full Text] [Related]
23. Altered expression of small heterodimer partner governs cytochrome P450 (CYP) 2D6 induction during pregnancy in CYP2D6-humanized mice.
Koh KH; Pan X; Shen HW; Arnold SL; Yu AM; Gonzalez FJ; Isoherranen N; Jeong H
J Biol Chem; 2014 Feb; 289(6):3105-13. PubMed ID: 24318876
[TBL] [Abstract][Full Text] [Related]
24. Recent examples on the clinical relevance of the CYP2D6 polymorphism and endogenous functionality of CYP2D6.
Haertter S
Drug Metabol Drug Interact; 2013; 28(4):209-16. PubMed ID: 24088607
[TBL] [Abstract][Full Text] [Related]
25. The endogenous substrates of brain CYP2D.
Wang X; Li J; Dong G; Yue J
Eur J Pharmacol; 2014 Feb; 724():211-8. PubMed ID: 24374199
[TBL] [Abstract][Full Text] [Related]
26. Cholic Acid Feeding Leads to Increased CYP2D6 Expression in CYP2D6-Humanized Mice.
Pan X; Kent R; Won KJ; Jeong H
Drug Metab Dispos; 2017 Apr; 45(4):346-352. PubMed ID: 28153841
[TBL] [Abstract][Full Text] [Related]
27. Constitutive expression and localization of the major drug metabolizing enzyme, cytochrome P4502D in human brain.
Chinta SJ; Pai HV; Upadhya SC; Boyd MR; Ravindranath V
Brain Res Mol Brain Res; 2002 Jun; 103(1-2):49-61. PubMed ID: 12106691
[TBL] [Abstract][Full Text] [Related]
28. P-glycoprotein is a factor in the uptake of dextromethorphan, but not of melperone, into the mouse brain: evidence for an overlap in substrate specificity between P-gp and CYP2D6.
Uhr M; Namendorf C; Grauer MT; Rosenhagen M; Ebinger M
J Psychopharmacol; 2004 Dec; 18(4):509-15. PubMed ID: 15582917
[TBL] [Abstract][Full Text] [Related]
29. The importance of heterogeneous nuclear ribonucleoprotein K on cytochrome P450 2D2 gene regulation: its binding is reduced in Dark Agouti rats.
Sakai N; Sakamoto KQ; Fujita S; Ishizuka M
Drug Metab Dispos; 2009 Aug; 37(8):1703-10. PubMed ID: 19420131
[TBL] [Abstract][Full Text] [Related]
30. Molecular mimicry rather than identity breaks T-cell tolerance in the CYP2D6 mouse model for human autoimmune hepatitis.
Ehser J; Holdener M; Christen S; Bayer M; Pfeilschifter JM; Hintermann E; Bogdanos D; Christen U
J Autoimmun; 2013 May; 42():39-49. PubMed ID: 23200317
[TBL] [Abstract][Full Text] [Related]
31. Discriminative quantification of cytochrome P4502D6 and 2D7/8 pseudogene expression by TaqMan real-time reverse transcriptase polymerase chain reaction.
Endrizzi K; Fischer J; Klein K; Schwab M; Nüssler A; Neuhaus P; Eichelbaum M; Zanger UM
Anal Biochem; 2002 Jan; 300(2):121-31. PubMed ID: 11779102
[TBL] [Abstract][Full Text] [Related]
32. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.
Neafsey P; Ginsberg G; Hattis D; Sonawane B
J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):334-61. PubMed ID: 20183526
[TBL] [Abstract][Full Text] [Related]
33. Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics.
Vuong C; Xie LH; Potter BM; Zhang J; Zhang P; Duan D; Nolan CK; Sciotti RJ; Zottig VE; Nanayakkara NP; Tekwani BL; Walker LA; Smith PL; Paris RM; Read LT; Li Q; Pybus BS; Sousa JC; Reichard GA; Smith B; Marcsisin SR
Antimicrob Agents Chemother; 2015 Jul; 59(7):3864-9. PubMed ID: 25870069
[TBL] [Abstract][Full Text] [Related]
34. Evolution of the CYP2D gene cluster in humans and four non-human primates.
Yasukochi Y; Satta Y
Genes Genet Syst; 2011; 86(2):109-16. PubMed ID: 21670550
[TBL] [Abstract][Full Text] [Related]
35. Sex steroid hormones differentially regulate CYP2D in female wild-type and CYP2D6-humanized mice.
Konstandi M; Andriopoulou CE; Cheng J; Gonzalez FJ
J Endocrinol; 2020 May; 245(2):301-314. PubMed ID: 32171179
[TBL] [Abstract][Full Text] [Related]
36. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
Preskorn SH; Kane CP; Lobello K; Nichols AI; Fayyad R; Buckley G; Focht K; Guico-Pabia CJ
J Clin Psychiatry; 2013 Jun; 74(6):614-21. PubMed ID: 23541126
[TBL] [Abstract][Full Text] [Related]
37. Farnesoid X Receptor Agonist Represses Cytochrome P450 2D6 Expression by Upregulating Small Heterodimer Partner.
Pan X; Lee YK; Jeong H
Drug Metab Dispos; 2015 Jul; 43(7):1002-7. PubMed ID: 25926433
[TBL] [Abstract][Full Text] [Related]
38. CYP2D6 in the brain: genotype effects on resting brain perfusion.
Kirchheiner J; Seeringer A; Godoy AL; Ohmle B; Maier C; Beschoner P; Sim EJ; Viviani R
Mol Psychiatry; 2011 Mar; 16(3):237, 333-41. PubMed ID: 20368706
[TBL] [Abstract][Full Text] [Related]
39. Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine.
He ZX; Chen XW; Zhou ZW; Zhou SF
Drug Metab Rev; 2015; 47(4):470-519. PubMed ID: 26574146
[TBL] [Abstract][Full Text] [Related]
40. Dopamine formation from tyramine by CYP2D6.
Hiroi T; Imaoka S; Funae Y
Biochem Biophys Res Commun; 1998 Aug; 249(3):838-43. PubMed ID: 9731223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]